UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES
EXCHANGE ACT OF 1934
For
the month of February 2026
Commission
File Number 001-40517
BON
NATURAL LIFE LIMITED
(Translation
of registrant’s name into English)
Room
601, Block C, Gazelle Valley, No.69, Jinye Road
High-Tech
Zone, Xi’an, Shaanxi, China
People’s
Republic of China
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report
to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on EDGAR.
Framework
Cooperation Agreement
On
January 22, 2026, our subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd (“App-Chem”) entered into entered into a
Framework Cooperation Agreement (the “Agreement”) with Shaanxi Chang’an Pilot Life Science Industry Innovation Center
Co., Ltd. (“Chang’an Pilot”).
Pursuant
to the Agreement, App-Chem and Chang’an Pilot have agreed to jointly establish an integrated innovation chain encompassing
fundamental research through to industrial application. The parties will co-establish the “BON & Pilot Natural Ingredients
and Biomanufacturing Joint Laboratory,” which will focus on research related to AI-driven biomanufacturing of natural ingredients.
The parties also intend to jointly establish an engineering center to promote process development, pilot-scale verification, and industrial
application of outcomes generated from the joint laboratory and other cooperative initiatives.
The
Agreement further contemplates comprehensive strategic collaboration in areas including technology research and development, market expansion,
and capital partnership, as well as potential capital collaboration through industrial funds, investment activities, mergers and acquisitions,
restructuring, and technology-driven financial mechanisms.
The
term of the Agreement is three years, and specific matters regarding the cooperation will be stipulated in separate formal agreements
to be entered into by both parties. The Agreement may be terminated by either party with three months’ prior notice or by mutual
agreement.
The
foregoing is a summary of the material terms of the Agreement. The Agreement contains additional terms, covenants and conditions and
should be reviewed in its entirety for additional information.
Exhibits
The
following exhibits are included in this Form 6-K:
| Exhibit
No. |
|
Description
of Exhibit |
| 10.1 |
|
Translation
of Framework Cooperation Agreement with Shaanxi Chang’an Pilot Life Science Industry Innovation Center Co., Ltd. |
| 99.1 |
|
Press
Release dated February 17, 2026 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| Date:
February 17, 2026 |
Bon
Natural Life Limited |
| |
|
|
| |
By: |
/s/
Yongwei Hu |
| |
|
Yongwei
Hu |
| |
|
Chairman
and Chief Executive Officer |
Exhibit 99.1
BON
Partners with Chang’an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing
XI’AN,
China - Feb. 17, 2026 — Bon Natural Life Limited (Nasdaq: BON) (“BON”or the “Company”), a leading
bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot
Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the “Joint Laboratory”). The Joint Laboratory was inaugurated
on December 18, 2025 through a collaboration between the Company’s domestic operating subsidiary, Xi’an App-Chem Bio-Tech
Co., Ltd., and Shaanxi Chang’an Pilot Life Science Industry Innovation Center Co., Ltd. (“Chang’an Pilot”).
The
Joint Laboratory will focus on the research and development of bio-manufactured natural active ingredients for use in functional foods
and personal care products. Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled
process optimization, the Joint Laboratory is intended to support the Company’s efforts to improve production efficiency, supply
reliability, and environmental sustainability compared to traditional plant-based extraction methods.
Founded
in 2006, BON operates in the development, manufacturing, and commercialization of natural active ingredients for applications in health
and personal care products. The Company’s product portfolio includes plant-derived extracts, functional food ingredients, and personal
care actives. BON serves customers in China, North America, the European Union, Japan, South Korea, and other international markets.
BON
possesses technical capabilities in natural ingredient extraction, separation, and biosynthesis, supported by a proprietary artificial
intelligence-enabled bio-manufacturing research and development platform designed to integrate data analytics and process engineering
for scalable production.
Chang’an
Pilot, established in 2022, provides laboratory infrastructure and research services focused on life sciences and artificial intelligence-enabled
manufacturing technologies.
Yongwei
Hu, Chairman of BON, stated, “We believe the establishment of this Joint Laboratory will strengthen our research capabilities and
create meaningful collaboration between our respective teams. We expect this initiative will support our continued efforts to develop
scalable, high-quality natural ingredients and advance our long-term growth strategy.”
About
Bon Natural Life Limited (“BON”)
BON
is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit
the Company’s website at http://www.bnlus.com.
For
more information, please contact:
Cindy
Liu | IR
Email:
bonnatural@appchem.cn
Safe
Harbor Statement
This
press release contains certain statements that may include “forward-looking statements.” All statements other than statements
of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified
by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known
and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements
are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s
actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors,
including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available
on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly
qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to
update these forward-looking statements.
